Latest Headlines

Latest Headlines

The metal-on-metal hip legal saga round one (of 6,000?): J&J vs. Herlihy-Paoli

Johnson & Johnson squared off with aggrieved metal-on-metal hip customer Kathleen Herlihy-Paoli in a case that the plaintiffs says could lead to a $5 billion-plus payout. Herlihy-Paoli's claims that the hips leaked metal into her bloodstream, leading to an infection that required the artificial hip to be removed.  

J&J shoring up for latest courtroom battle over all-metal hip implant

Long beleaguered by claims related to defective all-metal hip implants, Johnson & Johnson is shoring up for its latest courtroom battle as the company faces the first trial for one of its artificial hip devices.

J&J's DePuy, fearing fracture or limb-loss risks, recalls orthopedic implant part

Johnson & Johnson's DePuy arm is recalling multiple lots of an orthopedic implant part prone to fracturing in some cases, and the FDA slapped its most-serious Class I status onto the effort. Limb loss is listed as one of the risks.

Does J&J's latest metal hip lawsuit boost the number to 10,001?

With more than 10,000 lawsuits already in the mix, Johnson & Johnson must deal with yet another patient's allegation's that company knowingly sold faulty metal hip implants and didn't warn the public.

Stryker confronts mounting metal hip recall lawsuits

Stryker's bottom line is already taking a hit from the escalating cost of its all-metal hip recalls. But lawsuits against the device maker are also rising, threatening to grab an even bigger chunk of the company's cash.

J&J will abandon metal hip replacement sales

Johnson & Johnson has had enough with metal-on-metal and ceramic-on-metal hips, disclosing that it will leave those business lines entirely behind by the end of 2014.

UPDATED: For J&J, a hip lawsuit trial victory

After losing two jury trials, Johnson & Johnson/DePuy can now celebrate the fact that a jury has ruled in its favor regarding the company's ASR all metal hip implant.

Biomet's sales soar, losses widen after DePuy buyout

Biomet posted a 9% sales hike last quarter thanks largely to its $280 million acquisition of DePuy's trauma business, but a ramp-up in costs and a hefty impairment charge rocketed its net loss up about 184%.

J&J pressured to settle Australian hip lawsuits

Johnson & Johnson's $8.3 million defeat in a U.S. jury trial over its ASR metal-on-metal hip implant could force it to settle a massive class action lawsuit in Australia over the same product.

J&J's internal docs say recalled hip was defective

A Johnson & Johnson executive testified that the company recalled its all-metal hip replacements because they didn't meet "clinical expectations," not because they were defective, but that doesn't quite jibe with internal documents.